๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ovarian Cancer
Clinical trial register · China

Ovarian Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 24 Guangzhou 23 Shanghai 22 Wuhan 14 Chongqing 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Tongji Hospital7 AstraZeneca6 Fudan University6 Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd3 Sun Yat-sen University3
Site location
Beijing24 Guangzhou23 Shanghai22 Wuhan14 Chongqing13
All 50 locations
Target enrolment
to

Ovarian Cancer trials in China

94 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
NCT07822646Ovarian Cancer
DrugNab-paclitaxel
Chinese PLA General Hospital
Phase 3
120
Beijing, Tangshan, Taiyuan
2026-10-12
Not yet open
Trastuzumab Rezetecan and Carboplatin ยฑ Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
NCT07776171Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)
DrugsPegylated liposomal doxorubicin·Trastuzumab Rezetecan·Gemcitabine·Bevacizumab
Sun Yat-sen University
Phase 2
176
Guangzhou
2026-09-30
Recruiting
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
NCT07724106Ovarian Cancer, mRNA Vaccine
West China Hospital
Phase 1
9
Chengdu
2026-09-10
Recruiting
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
NCT07676890Ovarian Cancer, mRNA Vaccine
West China Hospital
Phase 1
9
Chengdu
2026-09-10
Not yet open
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
NCT07779538Ovarian Cancer
DrugsTrastuzumab·Bevacizumab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
420
Beijing, Zhejiang, Yunnan
2026-09-01
Recruiting
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
NCT07714668Ovarian Cancer, Recurrent Ovarian Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
171
Shanghai
2026-08-13
Not yet open
Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
NCT07593833Ovarian Neoplasms, Ovarian Cancer, Early Detection of Cancer
Tongji Hospital
Observational
1,000
Wuhan
2026-07-01
Recruiting
Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study
NCT07572409Ovarian Cancer
manxiaxia
Not applicable
52
Changchun
2026-07-01
Not yet open
Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer๏ผˆPhase II๏ผ‰
NCT07673835Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2
49
Shanghai
2026-06-06
Not yet open
NK521 in the Treatment of Advanced Solid Tumors
NCT07657416Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
DrugNK521 Cell
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2026-06
Recruiting
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
NCT07586826Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
DrugsAll-trans retinoic acid·Romiplostim N01
Peking University People's Hospital
Phase 2
220
Beijing
2025-12-22
Recruiting
A Study of LBL-024 in Combination With Paclitaxel ยฑ Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
NCT07042802Ovarian Cancer
DrugsLBL-024·Bevacizumab·Paclitaxel
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
By invitation
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
NCT03393962Ovarian Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2025-12-01
Recruiting
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
NCT07261683Ovarian Cancer, Immunotherapy, Pembrolizumab
Obstetrics & Gynecology Hospital of Fudan University
Phase 2
20
Shanghai
2025-12
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
DrugsBevacizumab·Carboplatin
AbbVie
Phase 1
219
Guangzhou, Jinan, Shanghai
2025-11-27
Recruiting
A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
NCT07544030Ovarian Cancer
tongweihua
Phase 3
60
Changchun
2025-11-10
Recruiting
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
NCT07532434Ovarian Cancer, Breast Cancer
Peking University Third Hospital
Observational
480
Beijing
2025-09-30
Recruiting
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT07156253Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1
110
Shanghai
2025-08-26
Not yet open
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
NCT07088588Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1
105
Shanghai
2025-07-31
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
NCT07612891Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
201
Shanghai
2025-07-04
Recruiting
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
NCT07033819Ovarian Cancer
DrugApatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
48
Beijing
2025-06-25
Recruiting
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
NCT07125391Ovarian Cancer
DrugsPropranolol·Carboplatin
Bai-Rong Xia
Phase 2
136
Hefei
2025-06-20
Not yet open
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT06990503Ovarian Cancer
DrugTrastuzumab Rezetecan
Tongji Hospital
Phase 3
300
Wuhan
2025-06-01
Not yet open
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
NCT06990516Ovarian Cancer
DrugsTrastuzumab Rezetecan·Oxaliplatin·Bevacizumab·Carboplatin
Tongji Hospital
Phase 1/2
90
Wuhan
2025-06-01
Not yet open
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
NCT06846424Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 1
24
Shanghai
2025-06-01
Recruiting
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
NCT06954584Ovarian Cancer
DrugsFluzoparib·Bevacizumab
Tongji Hospital
Phase 3
424
Wuhan
2025-05-27
Recruiting
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
NCT07023484Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsPaclitaxel·Carboplatin
The University of Hong Kong
Phase 2
126
Guangzhou, Shenzhen
2025-05-22
Recruiting
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
NCT07067255Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma, Ovarian Cancer Stage IV
Essen Biotech
Phase 1/2
80
Beijing
2025-04-29
Recruiting
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
NCT06890858Ovarian Cancer
DrugFasudil Hydrochloride
Zhejiang Provincial People's Hospital
Phase 2
20
Hangzhou
2025-04
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
NCT06840002Ovarian Cancer
DrugsDoxorubicin Hydrochloride Liposome·Trastuzumab Rezetecan·Adebrelimab·Oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
150
Wuhan
2025-03-18
Recruiting
A Study of SHR-A1811 in Subjects With Ovarian Cancer
NCT06828354Ovarian Cancer
DrugsDoxorubicin Hydrochloride Liposome·Topotecan·Trastuzumab Rezetecan·Gemcitabine
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Wuhan, Jinan
2025-03-13
Active, closed
METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NCT06884345Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 1/2
28
Hefei
2025-03-13
Recruiting
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06855069Ovarian Cancer
DrugsHS-20089·Topotecan·Doxorubicin·Paclitaxel
Hansoh BioMedical R&D Company
Phase 3
468
Beijing
2025-03-13
Recruiting
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
NCT06738966Breast Cancer, Ovarian Cancer, Endometrial Cancer
Shanghai Best-Link Bioscience, LLC
Phase 1
9
Changchun, Jinan
2025-03-10
Recruiting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
NCT06769152Cervical Cancer, Ovarian Cancer
DrugHLX43
Shanghai Henlius Biotech
Phase 2
190
Ji'nan
2025-02-20
Recruiting
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
NCT07285941Ovarian Cancer, HER2
DrugsDisitamab Vedotin·Carboplatin
Zhejiang Cancer Hospital
Phase 2
20
Zhejiang
2025-01-04
Recruiting
Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer
NCT07783022Ovarian Cancer
DrugNiraparib
Fudan University
Observational
1,920
Shanghai
2024-12-01
Not yet open
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
NCT06283875Ovarian Cancer
Geneplus-Beijing Co. Ltd.
Observational
80
Suzhou
2024-12-01
Recruiting
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
NCT06735326Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsFluzoparib·Bevacizumab·Paclitaxel·Carboplatin
Qilu Hospital of Shandong University
Phase 2
105
Jinan
2024-11-27
Recruiting
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
NCT06666270Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1
30
Zhengzhou, Shanghai
2024-11-21
Not yet open
Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence
NCT06558019Ovarian Cancer
Lei Li
Observational
509
Beijing
2024-10-01
Recruiting
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT06843629Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2024-10-01
Recruiting
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
NCT06873555Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
Heronova Pharmaceuticals
Phase 1/2
60
Bengbu, Changsha
2024-09-11
Not yet open
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
NCT06552858Ovarian Cancer
DrugsFluzoparib·Dalpiciclib
Fudan University
Phase 2
30
Shanghai
2024-09-01
Not yet open
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
NCT06544460Ovarian Cancer
Fudan University
Phase 2
94
Shanghai
2024-08-31
Recruiting
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT06437353Ovarian Cancer
DrugsSurufatinib·Paclitaxel·Carboplatin
Anhui Provincial Cancer Hospital
Phase 2
74
Hefei
2024-05-25
Recruiting
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06394492Ovarian Cancer
DrugsSHR-A1921·Topotecan·Doxorubicin·Paclitaxel
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
440
Beijing, Hangzhou
2024-05-10
Recruiting
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NCT06395844Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 1/2
28
Hefei
2024-05-01
Recruiting
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
NCT06251947Ovarian Cancer, Cervical Cancer
DrugEfbemalenograstim alfa
Shandong University
Phase 2
83
Changsha, Nanjing, Jinan, Qingdao, Taiyuan, Hangzhou
2024-04-15
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Active, closed
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT06483425Ovarian Cancer, Biomarker
Tongji Hospital
Observational
2,000
Wuhan
2024-03-01
Recruiting
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
NCT06215950Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
36
Wuhu
2024-01-10
Recruiting
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308Ovarian Cancer
Fudan University
Observational
168
Guangzhou, Shenyang, Shanghai
2023-12-18
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
DrugHS-20089
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
The Registry of Genetic Alterations of Taiwan Ovarian Cancer
NCT06127446Ovarian Cancer
National Health Research Institutes, Taiwan
Observational
300
2023-12-13
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT06010875Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
48
Nanchang
2023-11-30
Recruiting
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Observational
100
Hangzhou
2023-10-26
Not yet open
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
DrugsFluzoparib·Bevacizumab
Sun Yat-sen University
Phase 2
44
Guangzhou
2023-10-18
Active, closed
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
NCT06792435Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
Astellas Pharma Global Development, Inc.
Phase 1/2
240
Jinan
2023-07-27
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsTorvutatug samrotecan·Palacaparib·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
602
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
2023-06-05
Recruiting
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
NCT06562647Treatment Related Cancer, Ovarian Cancer
Cell Origin Biotech (Hangzhou) Co., Ltd.
Not applicable
2
Hangzhou, Linyi
2023-04-12
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Active, closed
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT05652283Ovarian Cancer
DrugsPamiparib·Surufatinib
Bai-Rong Xia
Phase 2
37
Hefei
2022-11-06
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
DrugsPrednisone/Prednisolone·Volrustomig·Xeloda·Rilvegostomig
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
NCT05551208Ovarian Cancer
Chongqing University Cancer Hospital
Phase 2
42
Chongqing
2022-08-15
Not yet open
Intraperitoneal Lidocaine in Ovarian Cancer Surgery
NCT05450055Ovarian Cancer, Post Operative Pain
Peking University Third Hospital
Not applicable
60
Beijing
2022-07-18
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugBevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05518253Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
Weijia Fang, MD
Phase 1
30
Hangzhou
2022-05-30
Recruiting
Chemotherapy Supported by Autologous Hematopoietic Stem Cells
NCT05401162Ovarian Cancer
Chongqing University Cancer Hospital
Not applicable
40
Chongqing
2022-04-15
Recruiting
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
NCT05206890Ovarian Cancer
DrugFluzoparib
Tongji Hospital
Observational
490
Wuhan
2022-01-14
Recruiting
A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics
NCT05251883Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
200
Guangzhou
2022-01-01
Recruiting
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
NCT04921527Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel
DrugsChiauranib·Paclitaxel
Chipscreen Biosciences, Ltd.
Phase 3
454
Shanghai
2021-12-20
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Bevacizumab·Paclitaxel·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Active, closed
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922Ovarian Cancer, Recurrent Cancer
DrugCYH33
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Recruiting
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
NCT04520074Ovarian Cancer
Fudan University
Phase 3
590
Shanghai
2021-10-08
Recruiting
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
NCT05446545Ovarian Cancer
Fudan University
Observational
139
Shanghai
2021-09-01
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
DrugOlaparib
AstraZeneca
Phase 3
366
Baoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang
2021-05-31
Recruiting
Lymphadenectomy in Early Ovarian Cancer
NCT04710797Ovarian Cancer, Lymphadenectomy
Sun Yat-sen University
Not applicable
656
Guangzhou
2021-01-31
Active, closed
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT04507841Ovarian Cancer
DrugNiraparib
Tongji Hospital
Phase 2
67
Wuhan
2021-01-08
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Datopotamab Deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Shanghai, Tianjin
2020-09-16
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
185
Changchun
2020-08-04
Active, closed
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
NCT04511871Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer
Shanghai PerHum Therapeutics Co., Ltd.
Phase 1
12
Shanghai
2020-07-09
Active, closed
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
NCT04169997Ovarian Cancer
Impact Therapeutics, Inc.
Phase 3
404
Guanzhou, Shanghai
2019-12-24
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230Ovarian Cancer
DrugPamiparib
BeiGene
Phase 3
224
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Harbin, Zhengzhou
2018-05-14
Recruiting
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
NCT02429687Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer
DrugsBleomycin·Etoposide·Paclitaxel·Cisplatin
Beihua Kong
Phase 3
129
Jinan
2015-04
Recruiting
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
NCT02429700Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer
DrugsBleomycin·Etoposide·Paclitaxel·Cisplatin
Beihua Kong
Phase 3
132
Jinan
2015-04
Recruiting
Shanghai Ovarian Cancer and Family Care Project
NCT06118307Ovarian Cancer
Shanghai First Maternity and Infant Hospital
Observational
3,546
Shanghai
2013-01-01
Rows per page Showing 1–94 of 94
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/ovarian-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 94 of those studies listing the condition Ovarian Cancer.

How many Ovarian Cancer trials are recruiting in China?

61 of the 94 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 15 have not yet opened recruitment, 17 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ovarian Cancer), 94 studies
PhaseStudiesRecruitingShare
Phase 2251626.6%
Phase 3191120.2%
Phase 1151116%
Phase 1/215916%
Observational141014.9%
Not applicable545.3%
Phase EARLY_PHASE1101.1%

Most active sponsors

Lead sponsors with the most studies (Ovarian Cancer)
Lead sponsorStudiesRecruiting
Tongji Hospital72
AstraZeneca63
Fudan University64
Anhui Provincial Cancer Hospital32
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd32
Sun Yat-sen University31
Suzhou Suncadia Biopharmaceuticals Co., Ltd.32
AbbVie21
Bai-Rong Xia21
BeiGene20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.